{"url_path":"/sec/aim/8-k/2026-07-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-033514-index.html","accession_number":"0001493152-26-033514","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-033514-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":741,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders**\n\n \n\nA\nSpecial Meeting of Stockholders (the “Special Meeting”) of AIM ImmunoTech Inc. (the “Company”) was held on July\n15, 2026. As of the record date for the Special Meeting, there were 27,724,245 outstanding shares of the Company’s common stock\noutstanding and entitled to vote at the Special Meeting. Of the record date outstanding shares, 10,671,690 shares, or approximately 38.5%,\nwere represented at the Special Meeting either in person or by proxy, meaning the requisite quorum for the meeting of 33 and 1/3% was\npresent.\n\n \n\nSet\nforth below are the matters voted upon at the Special Meeting, which are more fully described in the Company’s definitive proxy\nstatement filed with the U.S. Securities and Exchange Commission on June 25, 2026, and the final voting results received from the inspector\nof elections for the Special Meeting (the “Inspector of Elections”).\n\n \n\n**Proposal\n1: To approve, for purposes of complying with NYSE American Company Guide Sections 713(a) and 713(b), the issuance of more than 19.99%\nof the Company’s issued and outstanding shares of common stock, upon the exercise of the Class H common stock purchase warrants,\npursuant to the warrant exercise inducement offer letter agreement dated May 7, 2026:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n2,677,035\n \n1,312,258\n \n149,248\n \n6,533,150\n\n \n\nBased\non the final voting results reported by the Inspector of Election, Proposal 1 was approved.\n\n \n\n**Proposal\n2: To approve, for purposes of complying with NYSE American Company Guide Sections 713(a) and 713(b), the issuance of more than 19.99%\nof the Company’s issued and outstanding shares of common stock, upon the exercise of the Class I common stock purchase warrants,\npursuant to the securities purchase agreement dated May 20, 2026:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n2,676,038\n \n1,317,709\n \n144,794\n \n6,533,150\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 2 was approved.\n\n** **\n\n**Proposal\n3: To approve, for purposes of complying with NYSE American Company Guide Sections 713(a) and 713(b), the issuance of more than 19.99%\nof the Company’s issued and outstanding shares of common stock, upon the exercise of the Class J common stock purchase warrants,\npursuant to the securities purchase agreement dated June 9, 2026:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n2,684,308\n \n1,301,624\n \n152,610\n \n6,533,150\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 3 was approved.\n\n \n\n \n\n \n\n \n\n**Proposal\n4: To approve, for purposes of complying with NYSE American Company Guide Sections 713(a) and 713(b), the issuance of more than 19.99%\nof the Company’s issued and outstanding shares of common stock, upon the conversion or other satisfaction of that certain promissory\nnote dated February 16, 2024:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n2,676,665\n \n1,309,155\n \n152,722\n \n6,533,150\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 4 was approved.\n\n \n\n**Proposal\n5: To approve, for purposes of complying with NYSE American Company Guide Sections 713(a) and 713(b), the issuance of more than 19.99%\nof the Company’s issued and outstanding shares of common stock, upon the conversion or other satisfaction of that certain promissory\nnote dated November 18, 2025:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n2,673,399\n \n1,312,327\n \n152,816\n \n6,533,150\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 5 was approved.\n\n** **\n\n**Proposal\n6: To approve a series of alternate amendments to our Certificate of Incorporation to effect, at the option of our Board of Directors,\na reverse stock split of our outstanding common stock at a ratio in the range of up to 1-for-25, with such ratio to be determined by\nour Board of Directors in its sole discretion:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n7,344,727\n \n3,315,347\n \n11,616\n \n–\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 6 was approved.\n\n** **\n\n**Proposal\n7: To approve an adjournment of the Special Meeting to a later date or time, if necessary, to permit further solicitation of proxies\nif there are insufficient votes at the time of the Special Meeting to approve any of the other proposals presented for a vote at the\nSpecial Meeting:**\n\n \n\n**For:**\n** **\n**Against:**\n** **\n**Abstain:**\n \n**Broker\nNon-Votes:**\n\n7,380,255\n \n2,938,798\n \n352,637\n \n–\n\n** **\n\nBased\non the final voting results reported by the Inspector of Election, Proposal 7 was approved.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nAIM\nImmunoTech Inc.\n\n \n \n\nDate:\nJuly 16, 2026\nBy:\n\n*/s/\nThomas K. Equels*\n\n \n \nThomas\nK. Equels, CEO"}